← All news
Markets
Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Generalized Anxiety Disorder - Slideshow
Covered by 1 outlet
All coverage · 2 articles
Seeking Alpha
·Aug 12, 23:27 UTC
Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Generalized Anxiety Disorder Transcript
Seeking Alpha
·Aug 12, 20:34 UTC